Navigation Links
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
Date:9/29/2009

SAN DIEGO, Sept. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, October 6, 2009 at 2:00pm Eastern Time (11:00am Pacific Time) during the JMP Securities Healthcare Focus Conference at the Palace Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP, CFO
                Cadence Pharmaceuticals, Inc.
                858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Canaccord Adams Global Growth Conference in Boston on August 11, 2009
2. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
3. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
6. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
7. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
10. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
(Date:11/27/2014)... VogueQueen.com is making every effort to offer more affordable ... the premier online supplier of elegant special occasion dresses ... huge selection of sexy prom dresses today. In addition ... many beautiful styles in its product line. Click to ... , “VogueQueen.com hopes to provide a truly unique shopping ...
(Date:11/27/2014)... Aliso Viejo, California (PRWEB) November 27, 2014 ... have announced a new plugin entitled ProPip, taking FCPX to ... picture in picture effect with a few clicks of a ... is a time saver that our users will appreciate.” , ... with full customization leaving the possibilities truly endless. ProPip is ...
(Date:11/27/2014)... 2014 HealthPostures, a leading ... , has announced that it has entered into ... The partnership will put HealthPostures' products into central ... In addition to having its products sold through ... HealthPostures' products with the business decision makers in ...
(Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... pediatric combination for, immunization against diphtheria, tetanus, pertussis, polio and ... ... Pa. and LYON, France, June 23 Sanofi,Pasteur, the vaccines ... and Drug Administration (FDA) has licensed Pentacel(R),Diphtheria and Tetanus Toxoids ...
... decrease in health care and compensation benefits, ... economy, employers are managing to maintain a balance ... Survey released today by,the Society for Human Resource ... health care costs, combined with the state of ...
... NEW YORK, June 21 Many professionals,world-wide are calling ... force fluoridation on almost the whole state. SB 312 ... most Louisianans knowing,it was happening. The professionals are asking ... Citizens should have been part of this discussion,but they ...
... DELHI, India, June 20 The United States,has ... Save the Children to assist people affected by ... Shortages have emerged in recent months because ... in rapidly growing rat infestations in,crop-growing areas. With ...
... San Francisco,Medical Society (SFMS) announces the "David Perlman ... is presented each January at,the SFMS Annual Dinner ... television, radio and newspapers and magazines. The deadline ... award., A prestigious panel of SFMS journalists, ...
... life is greatly improved, too, , , FRIDAY, June 20 ... for many people with kidney disease, it can be ... blood as effectively as well-functioning kidneys do. , But, ... to change all that. , Nocturnal dialysis, not surprisingly, ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Despite Economic Downturn, Employee Benefits Remain Stable in 2008 2Health News:Professionals Ask Governor Jindal to Veto Unfair Fluoridation Bill 2Health News:SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 3
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... MINNEAPOLIS, Sept. 29 ProUroCare Medical Inc. (OTC Bulletin ... imaging products, today announced the signing of an agreement ... LP of Juno Beach, Fla.  The proceeds of the ... portfolio and to support scale-up activities associated with final ...
... PROSPECT, Ill., Sept. 29 Earlier this year, the National ... was introduced to the AWARxE campaign, which was created and ... the power of the campaign, NABP obtained the AWARxE program ... level. The Foundation was inspired to create ...
Cached Medicine Technology:UPDATE - ProUroCare Announces $3 Million Financing Agreement 2UPDATE - ProUroCare Announces $3 Million Financing Agreement 3NABP Purchases AWARxE Consumer Protection Program 2
Sonogage introduces a new generation of A-Scan biometers for visual axis measurements and IOL calculations. The Eye-Scan™ employs the latest electronic and transducer technologies for unsurpass...
... three conventional measurement modes (Phakic, Aphakic, and ... new axial length measuring mode. Normal phakic ... velocity for conversion at 1550m/s. The new ... each tissues sonic velocity for conversion: anterior ...
... the world's first very high frequency digital ... technology, Artemis provides microscopic resolution images and ... anterior segments of the human eye. Artemis ... eye scanner. In use, the patient leans ...
... The new OTI-Scan 1000 is the ... compact combination B/A-scan system operates with a ... performs 3D B-scans with a streamlined internal ... 1000 is newly designed. The UltraFast 12 ...
Medicine Products: